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Abstract
Background: Streptococcus pneumoniae is a commensal of the human upper respiratory tract and a major cause of
morbidity and mortality worldwide. This paper presents the distribution of serotypes and antimicrobial resistance in
commensal S. pneumoniae strains cultured from healthy carriers older than four years of age in nine European
countries.
Methods: Nasal swabs from healthy persons (age between 4 and 107 years old) were obtained by general practitioners
from each country from November 2010 to August 2011. Swabs were cultured for S. pneumoniae using a standardized
protocol. Antibiotic resistance was determined for isolated S. pneumoniae by broth microdilution. Capsular sequencing
typing was used to identify serotypes, followed by serotype-specific PCR assays in case of ambiguous results.
Results: Thirty-two thousand one hundred sixty-one nasal swabs were collected from which 937 S. pneumoniae were
isolated. A large variation in serotype distribution and antimicrobial resistant serotypes across the participating countries
was observed. Pneumococcal vaccination was associated with a higher risk of pneumococcal colonization and antimicrobial
resistance independently of country and vaccine used, either conjugate vaccine or PPV 23).
Conclusions: Serotype 11A was the most common in carriage followed by serotypes 23A and 19A. The serotypes showing
the highest resistance to penicillin were 14 followed by 19A. Serotype 15A showed the highest proportion of multidrug
resistance.
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Background
Streptococcus pneumoniae (pneumococcus) is a com-
mensal of the human upper respiratory tract [1] and a
major cause of morbidity and mortality worldwide.
Pneumococcal disease has various manifestations includ-
ing otitis media, pneumonia, septicemia and meningitis
[2]. Incidence of the disease is highest at extremities of
life: in very young children and in the elderly. Based on
capsular polysaccharide chemistry and immunogenicity,
over 90 distinct capsular types (serotypes) have been
identified so far [3].
Two types of pneumococcal vaccines are commercially
available: a pneumococcal polysaccharide vaccine (PPV)
and pneumococcal conjugate vaccines (PCVs). Currently
used PPV (Pneumovax 23) was first introduced in 1983
and by targeting 23 pneumococcal serotypes (1, 2, 3, 4,
5, 6B, 7F, 8, 9 N, 9 V, 10A, 11A, 12F, 14, 15B, 17F, 18C,
19A, 19F, 20, 22F, 23F, 33F) has valency broader than
any PCV. However, unlike PCVs, PPV is not effective in
very young children. Three different PCV’s are in use.
The seven-valent vaccine (Prevnar, PCV7) was intro-
duced in 2000, followed in 2009 by ten-valent (Synflorix,
PCV10) and in 2010 by thirteen-valent (Prevenar13,
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PCV13) vaccines. PCV7 comprises serotypes 4, 6B, 9 V,
14, 18C, 19F and 23F, PCV10 includes additional sero-
types 1, 5 and 7F, and PCV13 contains extra serotypes 3,
6A and 19A.
The introduction of PCVs into infant immunization pro-
grams has led to a major decrease in vaccine serotype (VT)
disease in vaccinated children but to a various degree also
resulted in herd effects across whole populations [4]. These
indirect effects in unvaccinated individuals were caused by
reduction of VT strain carriage in young children who are
the main reservoir and main transmitters of pneumococci
[5, 6]. PCVs may also contribute to a decrease in overall in-
cidence of antimicrobial resistant pneumococcal disease
[7]. This effect was augmented by the fact that VT strains
were usually more resistant to antibiotics compared to
non-vaccine (NVT) strains [7]. However, long term benefits
of PCVs were eroded by the emergence of (multidrug-resis-
tant) NVTs in carriage and in disease, the so called
vaccine-induced serotype replacement [8].
There are differences in the timing of vaccine introduc-
tion, vaccination policies and vaccine coverage among
countries that implemented PPV and PCVs into their Na-
tional Immunization Programs (NIPs) [9]. This could result
in differences in direct and herd effects, in serotype replace-
ment and in resistance to anti-pneumococcal drugs in
strains circulating in carriage and causing disease. By the
end of 2012, 26 of the 53 countries of the European region
vaccinated infants with PCVs in their NIPs [9]. In 2011, the
PCVs coverage in infants’ vaccination (after administration
of a minimum of 3 doses of vaccine by the age of 2 years)
was more than 90% in these 26 European countries [9]. To
our knowledge, there are no studies that evaluated the sero-
type distribution in commensal pneumococcal populations
and its relationship with antimicrobial resistance across
European countries as well as the impact of pneumococcal
vaccination in a multicentre surveillance on pneumococcal
carriage.
In this report, we assessed serotypes and resistance to
antimicrobial agents of S. pneumoniae strains cultured
from healthy carriers older than four years of age in nine
European countries that differed in the timing of
pneumococcal vaccines introduction, vaccines schedule
and coverage, vaccines used (PCVs and PPV) and pres-
ence of catch-up campaigns. Results were analysed for
impact of pneumococcal vaccination (immunization
status) on individual person level and for effects that
could be linked to differences in pneumococcal vaccin-
ation programs.
Methods
Study design
S. pneumoniae strains were cultured from samples col-
lected from November 2010 to August 2011, as a part of
the ‘The Appropriateness of prescribing antimicrobial
agents in primary health care in Europe with respect to
antimicrobial resistance’ (APRES) study as described by
van Bijnen et al. [10]. Briefly, general practitioners (GP)
from Austria, Belgium, Croatia, France Hungary, Spain,
Sweden, the Netherlands and the United Kingdom (9
countries, 20 GPs per country), were each asked to pro-
vide nasal swabs from 200 healthy persons (with no his-
tory of antibiotic therapy or hospitalization in the
previous three months), older than 4 years (except for
UK, where for ethical reasons patients were older than
18 years). Within 48 h after collection swabs were trans-
ported to each national laboratory for further processing,
with the exception of samples collected in France that
were all sent to the Dutch national laboratory at Maas-
tricht University Medical Centre (MUMC). On arrival to
diagnostic labs, samples were cultured for S. pneumoniae
using a standardized protocol [10]. Putative S. pneumo-
niae isolates from all participating countries were sent to
the MUMC in skimmed milk at -80 °C for further
analysis.
All participants provided written informed participa-
tory consent and in the case of children aged less than
16, their parents or guardians provided written informed
participatory consent on their behalf. All methods were
approved by named institutional committee and were
performed in accordance with relevant guidelines and
regulations.
Capsular sequence typing (CST)
CST was performed in the National Institute for Pub-
lic Health and the Environment, Bilthoven, The
Netherlands as previously described by Elberse et al.
[11]. Briefly, culture of S. pneumoniae in Brain Heart
Infusion broth with 0,5% yeast extract, incubated over-
night at 37 °C and 5% CO2, was heated at 95 °C for
10 min and used as a DNA template in PCR to amplify
a fragment of the capsular wzh gene. Amplicons were
sequenced by BaseClear BV, Leiden, The Netherlands.
Sequences generated were assembled, edited and
trimmed using Bionumerics v6.1 (Applied Maths,
Sint-Maartens-Latem, Belgium) and assigned a capsu-
lar sequence type (CT) using the CST database
(https://www.rivm.nl/mpf/typingtool/spn/). CT is a
composite assignment, in which the first part repre-
sents the serotype assessed by conventional serotyping
(Quellung) followed by the number representing a
consecutive wzh allele identified among strains of a
given serotype [11]. When an allele not yet recorded
in CST database was found, serotype of an isolate was
determined by Quellung method at the Netherlands
National Reference Laboratory for Bacterial Meningi-
tis (NRBM), Amsterdam, the Netherlands.
For statistical analysis feasibility, isolates were grouped by
serotype and not by individual CTs. For CTs associated
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with a single serotype (61 of the 79 CST types found in this
study), grouping was based on the first part of the CST as-
signment. For CTs represented by multiple serotypes, par-
ticularly those concerning vaccine serotypes, additional
PCR and/or PCR-sequencing assays were performed as fol-
lows. For CTs representing serogroup 6 isolates, distinction
between 6A/B and 6C/D was made using primers specific
for wciNbeta, after which 6A and 6B were distinguished by
PCR sequencing of wciP as described [12]. For CTs 15B-01,
15C-01, 22F-01, 23F-01, and 24F-01, the appropriate
serotype-specific primers from the protocol of the CDC for
multiplex PCR serotype deduction (http://www.cdc.gov/
streplab/pcr.html) were used in single PCR. For isolates of
CT 34–01, PCR-sequencing of the wzg gene was performed
to distinguish between serotype 17 and 34 isolates. Finally,
distinction between CT 25F-02-associated serotypes 25A/F
and 38 was achieved by PCR-amplification of the wcyV
gene. When no gene was amplified with the used primers
and no CST could not be assigned, isolates were considered
as not typable. Primers used for these additional PCR assays
are shown in Additional file 1: Table S5.
Antimicrobial susceptibility
All isolates were tested for susceptibility to ceftazidime,
clarithromycin, clindamycin, penicillin, tetracycline and
trimethoprim-sulfamethoxazole. Minimal inhibitory concen-
trations of these drugs were assessed by broth microdilution
method in accordance with EUCAST guidelines and
EUCAST epidemiological cut-offs were applied as break-
points [13]. Multidrug resistance was defined as resistance to
three or more classes of antimicrobial agents.
Data analysis
In order to study the effect of vaccination on pneumo-
coccal carriage and antimicrobial resistance, a multilevel
logistic regression was performed. To account for
non-random clustering of our data at family level and to
control whether age and gender affects pneumococcal
carriage prevalence, a 3-level multilevel logistic regres-
sion model (country, GP and patient) was estimated
using MLWIN software package. Statistical analysis was
performed using the PASW software package 19.0, with
p-value < 0.05 considered statistically significant.
Results
Participants and bacterial strains
Table 1 shows the demographic background of the par-
ticipating individuals. In total, 31,625 individuals were
recruited, varying from 3969 in Spain to 3025 in
Belgium. The proportion of males ranged between 39.9%
in Croatia and 45.6% in Belgium. Working in the health-
care sector ranged between 2.2% in Hungary to 16.5% in
Sweden and working in nursery between 1% in Croatia
to 4.1% in Sweden. Living with children < 5 years of age
Table 1 Demographic overview of the participant individuals (in %)
Austria Belgium Croatia France Hungary Netherlands UK Spain Sweden
Gender of patient
Man 42.8 45.6 39.9 44.5 44.2 41.6 40.6 41.6 42.3
Women 55.8 53.9 58.5 54.5 54.2 55.7 58.8 58.4 57.2
Unknown 1.4 0.5 1.6 1.0 1.6 2.7 0.6 0.0 0.5
Age in year category
4–9 1,2 1,3 6.0 3,3 8,5 3,2 0.0 4,9 5,4
10–17 2,2 3,1 8,2 4,7 15,6 5,3 0.0 5,9 5,4
18–29 15,8 8,2 9,2 11,5 9,6 11,1 14,7 9,2 9,6
30–60 50,2 40,9 38,8 45,2 36,5 45,7 46,3 41,5 37,7
> 60 29,8 46,5 37,4 34,9 29,1 33,9 38,8 38,5 41,6
Job in Healthcare sector
Yes 6,0 4,6 3,7 3,1 2,2 10,3 8,8 3,3 16,5
Job in nursery
Yes 1,9 2,2 1,0 2,1 3,4 3,0 2,4 2,0 4,1
None from the above-mentioned jobs or unknown
Yes 92,1 93,2 95,3 94,8 94,4 86,7 88,8 94,8 79,4
Do you live with children of 5 years and younger?
Yes 11,8 10,1 13,6 14,2 11,1 13,7 13,9 14,0 16,1
No 87,1 89,9 85,6 85,2 86,2 84,6 85,2 82,0 82,8
unknown 1,1 0,0 0,8 0,6 2,7 1,7 0,9 4,0 1,1
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was between 10.1% in Belgium and 16.1% in Sweden.
Among all participants, 937 were identified as pneumo-
coccal carriers and ranged between170 in France to 36
in UK.
Pneumococcal vaccination policy in the participating
countries
Seven of the nine participating countries had introduced
a pneumococcal conjugate vaccine in their NIP before
November 2010 (Additional file 1: Table S1a) and used
PCV7 during one (Sweden) to six years (Austria) prior
to study onset. The exceptions were Croatia and Spain,
two countries that only have risk-based pneumococcal
vaccination programs. France was the only country with
vaccination of risk group patients in the NIP in addition
to infants. In Austria, Belgium, France and Sweden,
PCV13 and PPV23 were used in adults and in risk popu-
lations (Additional file 1: Table S1b). In the Netherlands
and Spain, only PPV23 was used in adult and on
risk-based immunization. In Hungary, no recommenda-
tions were in place for vaccination of elderly and risk pa-
tients (Additional file 1: Table S1b).
Vaccination status among participants
Among all participants, 10.3% (n = 3316) were vacci-
nated, 79.0% (n = 25,404) were not, and 10.7% (n = 3441)
had an unknown vaccination status. Among carriers,
Spain had the highest percentage of vaccinated individ-
uals (30.5%) and Croatia the lowest (0.7%) (Table 2). In
all countries except Austria and Belgium, participants
between 4 and 9 years old were more frequently
vaccinated than those older than 10 years (p < 0.0001;
Additional file 1: Table S2).
Serotype carriage in the participating countries
Serotype 11A was the most common in carriage in the
study population (n = 60) followed by serotypes 23A (n =
58), 19A (n = 52), 3 (n = 51), 6C (n = 44) and 23B (n = 39).
All these serotypes were considered as non-PCV types
since none was targeted by either PCV7 or PCV10 used in
the study populations at the time of sample collection.
These serotypes were followed by 19F (n = 38) and 23F (n
= 37), targeted by all commercially available pneumococcal
vaccines. Serotype 23F was the most frequent among S.
pneumoniae carriage isolates in Croatia (n = 15 of 134,
11.2%) one of two countries without PCVs in NIP. Serotype
23F was along with serotype 11A (n = 11 of 103, 10.7%
each) also most common in carriage in Sweden, country
with shortest PCV immunization program at the time the
study was conducted (Additional file 1: Table S1a and b).
Serotype 6C was the most common in the Netherlands (n
= 11 of 129, 8.5%) and Spain (n = 11 of 167, 6.6%). Serotype
3 (n = 6, 14.0%), 15A (n = 6, 12.8%), 11A (n = 18, 10.6%)
and 10A (n = 5, 13.9%) were the most common in Austria,
Belgium, France and UK, respectively. Serotypes 23A and
15 B/C (n = 9, 7.8%) were the most common in Hungary
(Table 3 and Additional file 1: Table S3).
Serotypes 17F and 22F, both targeted by PPV23
vaccine, were significantly associated with age older than
10 years (p = 0.03 and p = 0.01, respectively). Serotype
23F (PCV7 serotype) was significantly associated with
age 4–9 years (p = 0.01). Other serotypes were not asso-
ciated with any age category (Additional file 1: Table S4).
Vaccination effect on pneumococcal colonization and
serotypes
Among the pneumococcal carriers (all serotypes consid-
ered), 115 were vaccinated and 727 were not vaccinated,
while the vaccination status was unknown for 95
individuals.
Table 4 shows the effect of pneumococcal vaccination
on pneumococcal carriage. Being vaccinated was associ-
ated with a higher risk of pneumococcal colonization.
None of the variables i.e. vaccine regimen, the presence
Table 2 Vaccination status of participants per country
Total participants
population
Vaccinated
participants
N (%)
Non-vaccinated
participants
N (%)
Participants with
unknown status
N (%)
S.pneumoniae
isolated
N (%)
Vaccinated
carriers
%
Austria 3309 193 (5.8) 2254 (68.1) 862 (26.1) 38 (1.1) 5.3
Belgium 3025 493 (16.3) 2475 (81.8) 57 (1.9) 44 (1.5) 15.9
Croatia 3952 27 (0.7) 3763 (95.2) 162 (4.1) 134 (3.4) 0.7
France 3857 197 (5.1) 3368 (87.3) 292 (7.6) 170 (4.4) 13.5
Hungary 3832 134 (3.5) 3484 (90.9) 214 (5.6) 116 (3.0) 5.2
Netherlands 3847 89 (2.3) 3012 (78.3) 746 (19.4) 129 (3.4) 6.2
Spain 3969 1109 (27.9) 2691 (67.8) 169 (4.3) 167 (4.2) 30.5
Sweden 3214 304 (9.5) 2411 (75.0) 499 (15.5) 103 (3.2) 6.8
UK 3156 770 (24.4) 1946 (61.7) 440 (13.9) 36 (1.1) 27.8
Total 32,161 3316 (10.3) 25,404 (79.0) 3441 (10.7) 937 (2.9) 12.3
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of a catch-up campaign, the year of the vaccine imple-
mentation, the vaccine type, or the extent of vaccination
program had separately a significant effect on pneumo-
coccal colonization. Of 937 pneumococcal strains cul-
tured from carriers, 170 (18.1%) were of PCV10 types.
Of these 149 (15.9% of the total number of strains) were
of PCV7. There were significantly fewer carriers of
PCV10 serotypes among vaccinated (11 of 115, 9,6%)
compared to non-vaccinated individuals (138 of 727,
19.0%), p = 0.01 (Table 5). These findings in combination
with Table 4 suggest that vaccinated individuals have
more chance to be colonized by non-vaccine serotypes.
Table 6 shows the antimicrobial resistance per
serotypes. The highest resistance proportion to
ceftazidime and penicillin was noticed among serotype
14 strains (13 of 16, 81.3%). Serotype 14 was the most
frequent serotype showing resistance to penicillin,
followed by serotype 19A and 15A. Among serotypes
with more than 10 isolates, paediatric serotypes (6B,
9 V, 14, 19F and 23F) were more resistant to anti-
microbial agents than non-paediatric serotypes (1, 3,
4, 7F). The serotypes presenting the highest propor-
tion of multidrug resistance were 15A followed by 19A
and 14. Serotypes 6C, 23B, 15A, 19A, 6A and 19F
were significantly more prevalent whereas serotypes
22F, 23A, 3 and 14 were significantly less prevalent in
the multidrug resistant fraction compared to the total
study collection (Table 6).
Table 3 Serotypes distribution by country (%). Serotypes listed in order from highest to lowest in frequency among all S. pneumoniae
strains cultured in the study as reported in the last column
Serotype Austria
N = 38
Belgium
N = 44
Croatia
N = 134
France
N = 170
Hungary
N = 116
Netherlands
N = 129
Spain
N = 167
Sweden
N = 103
UK
N = 36
Total
N = 937
11A 5.3 6.8 2.2 10.6 6.9 7.0 2.4 10.7 5.6 6.4
23A 2.6 2.3 6.7 7.6 7.8 4.7 4.8 7.8 8.3 6.2
19A 2.6 2.3 7.5 8.2 0.9 6.2 4.8 5.8 8.3 5.5
3 15.8 0.0 3.7 9.4 4.3 4.7 5.4 2.9 2.8 5.4
6C 5.3 4.5 3.0 5.3 0.9 8.5 6.6 1.9 5.6 4.7
NT 5.3 9.1 3.7 4.7 3.4 7.0 3.6 3.9 2.8 4.6
23B 5.3 6.8 0.0 7.1 0.0 7.0 5.4 1.9 5.6 4.2
19F 5.3 0.0 6.7 3.5 5.2 3.1 3.0 4.9 2.8 4.1
23F 5.3 0.0 11.2 0.0 0.9 2.3 1.2 10.7 8.3 3.9
15B/C 7.9 2.3 0.7 2.4 7.8 1.6 4.8 3.9 8.3 3.7
35B 2.6 2.3 2.2 5.3 6.9 1.6 3.6 1.9 5.6 3.6
35F 2.6 4.5 3.0 2.9 5.2 1.6 1.2 8.7 5.6 3.5
22F 2.6 4.5 1.5 4.7 2.6 3.9 2.4 4.9 5.6 3.4
6A 7.9 0.0 7.5 1.2 3.4 3.1 1.2 2.9 0.0 3.0
10A 0.0 2.3 0.0 1.2 6.0 4.7 4.2 0.0 13.9 3.0
6B 0.0 0.0 6.7 0.6 1.7 6.2 1.2 2.9 0.0 2.7
15A 2.6 13.6 0.7 3.5 0.0 1.6 3.6 1.9 0.0 2.6
17F 0.0 2.3 0.0 3.5 3.4 4.7 3.0 0.0 2.8 2.5
24F 0.0 4.5 0.0 2.9 5.2 0.8 4.2 0.0 0.0 2.2
18C 0.0 0.0 0.7 0.0 6.0 3.1 1.2 5.8 0.0 2.1
16F 0.0 2.3 0.7 0.6 4.3 0.8 5.4 1.0 0.0 2.0
7F 2.6 6.8 1.5 1.2 0.0 2.3 3.0 1.9 0.0 1.9
9 N 0.0 2.3 5.2 0.6 0.9 2.3 1.2 1.9 0.0 1.8
37 2.6 0.0 3.0 0.0 1.7 3.1 3.0 1.0 0.0 1.8
14 0.0 2.3 3.7 0.0 1.7 0.0 4.2 1.0 0.0 1.7
33F 0.0 0.0 0.0 2.4 0.9 2.3 1.8 3.9 0.0 1.6
34 0.0 0.0 2.2 0.0 3.4 0.8 1.8 1.9 0.0 1.4
21 0.0 0.0 0.0 3.5 0.9 0.0 3.0 0.0 2.8 1.4
31 0.0 9.1 0.7 1.2 2.6 0.0 1.2 0.0 0.0 1.3
UK United Kingdom; in bold: serotypes with the highest frequency in a country, NT not typable. Only serotypes represented by more than 10 strains among all S.
pneumoniae strains cultured in the study are reported. Complete overview of serotypes is shown in Additional file 1: Table S3
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Vaccination effect on antimicrobial resistance carriage
Table 7 shows the effect of vaccination on carriage of
antimicrobial resistant pneumococcal isolates. Being vac-
cinated enhanced carriage of isolates resistant to at least
one of the tested antimicrobial agents (model 1, OR =
0.60, p = 0.03). After adding different vaccination pro-
gram characteristics (vaccine dose, conduction of
catch-up campaign, period since vaccine was imple-
mented, vaccine type and extent of vaccination program)
separately, none of these could explain alone the vaccin-
ation effect (models 2–6).
Discussion
In this report, we assessed serotypes and resistance to
antimicrobial agents of S. pneumoniae strains cultured
from healthy carriers older than four years of age in nine
European countries that differed in the timing of
pneumococcal vaccines introduction. A large variation
was found in serotype distribution in the participating
countries and we observed difference in antimicrobial
resistance including multidrug resistance, among these
serotypes. The major finding was that pneumococcal
vaccination was associated with a high risk of non
PCV10 serotypes carriage.
This study was carried out on a large and well docu-
mented population, covering different age groups. To
eliminate intra-laboratory variations, all methods were
conducted in a central laboratory per method (suscepti-
bility testing in MUMC, molecular serotyping in RIVM
and conventional serotyping using Quellung method in
NRBM). These points allowed us to accurately address
the goals of this study. However, drawbacks were differ-
ences in numbers of strains collected and tested per
country with significantly fewer strains from UK, Austria
and Belgium (p < 0.0001) compared to any other partici-
pating sites. This could limit the generalization of our
findings to the entire population in those countries. Pos-
sible explanation for differences in prevalence of carriage
Table 4 Relationship between vaccine-related variables (number of doses, presence of catch up campaign, year of implementation,
vaccine type and extent of vaccination program), and pneumococcal carriage in the participating individuals
Models Reference variable Comparative variables OR* p value**
Basic model:
Model 1: vaccination Vaccinated Not vaccinated 0.70 (0.55–0.89) 0.00**
Unknown vaccination
status
0.76 (0.54–1.05) 0.10
Models after addition vaccination program characteristics separately:
Model 2: vaccine dose 2 + 1b 3 + 1a 1.39 (0.66–2.92) 0.37
Model 3: catch up campaign conduction Catch up campaign conductedc No catch up campaign
conductedd
0.76 (0.54–1.05) 0.41
Model 4: period since the vaccine implementation implemented for one year implemented for more
than one year
1.05 (0.88–1.25) 0.53
Model 5: type of vaccine PCV 7 PCV 7, PCV10 and
PCV 13
1.00 (0.39–2.55) 0.98
PCV 10 and PCV 13 0.80 (0.31–1.87) 0.65
Model 6: extent of vaccination program risk based and universal e Risk based g 0.57 (0.17–1.87) 0.36
Universal f 0.43 (0.14–1.33) 0.14
*OR adjusted for countries, age and general practitioner; **p < 0.05 is significant
Table 5 distribution of vaccine and non-vaccine serotypes in vaccinated and non-vaccinated among the study population
Serotype carried Vaccinated Non-vaccinated Unknown Total
PCV7 serotypes a 9 121 19 149
PCV10-PCV7 serotypes b 2 17 2 21
PCV13-PCV10 serotypes c 15 103 13 131
No vaccine type or PCV serotypes d 0 2 0 2
Non-PCV13 vaccine types 88 477 61 626
PPV23 serotypes f 50 396 54 500
Non-PPV23 vaccine types 65 331 41 437
Not determinate 1 7 0 8
aserotypes 4, 6B, 9V, 14, 18C, 19F and 23F; b serotypes 1, 5 and 7F; c serotypes 3, 6A and 19A; d serotypes 18For 18C (the serotyping method is not able to
differentiate between serotypes 18F(NVT) and 18C (VT)); f serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F
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could be differences in age of sampled individuals (e.g.
no minors under age of 18 years were sampled in UK)
or in patterns of social contacts with very young chil-
dren: carriage rates in parents of young children are re-
ported to be few-fold higher compared to childless
adults [14].
This study cannot be used to assess the spread and
antimicrobial resistance in S. pneumoniae among non-
vaccinated persons. This would require a longitudinal
study. Furthermore, many factors determine carriage
and resistance (e.g. antibiotic use was exclusion crite-
rium in this study, seasonal variations in pneumococcal
carriage), so one needs to be careful with drawing gen-
eral conclusion based on these results.
For feasibility and costs considerations, capsular se-
quence typing was used in the primary method of
serotyping. When highly frequent or vaccine CST’s
could not be differentiated, additional PCR’s were per-
formed. Conventional serotyping with type-specific sera
was performed only when results generated with the
CST method were equivocal. Our results support CST as
a method alternative to the conventional Quellung sero-
typing in epidemiological studies.
PCV-7 was licensed in Europe in 2001. Higher valency
vaccines were introduced since then (PCV-10 and
PCV-13 in 2009 and 2010, respectively). If our results
represented the effects of any vaccine in the studied
population, these should be likely indirect (herd) effects
of PCV7, and without any contribution of PCV13 since
this vaccine was implemented after our study onset.
The most frequent serotypes among the carriage iso-
lates were 11A, 19A, 3, 6C, 23A and 23B. All these
Table 6 Distribution of antimicrobial resistance by serotype. Only serotypes represented by more than 10 isolates are reported.
Correlation between frequency of serotypes in study population and in MDR fraction is given in the last column
serotypes N (%) Ceftazidime
(%)
Clarithromycin
(%)
Clindamycin
(%)
Penicillin
(%)
Tetracyclin
(%)
Trimethropim/
sulfamethoxazole (%)
MDR Fraction
N (%)
p value
11A 60 (6.4) 8.3 6.7 3.3 5.0 0.0 10.0 5 (8,3) 0.090
23A 58 (6.2) 0.0 19.0 19.0 1.7 19 24.1 2 (3,4) 0.007*
19A 52 (5.5) 67.3 53.8 50 67.3 55.8 30.8 32 (61,5) < 0.001*
3 50 (5.3) 0.0 0.0 0.0 0.0 0.0 2.0 0 (0,0) 0.001*
6C/D 44 (4.7) 6.8 29.5 27.3 27.3 25.0 0.0 11 (25,0) 0.001*
23B 39 (4.2) 12.8 0.0 0.0 30.8 0.0 28.2 11 (28,2) 0.093
19F 37 (3.9) 32.4 56.8 48.6 37.8 54.1 18.9 14 (37,8) 0.001*
23F 37 (3.9) 13.5 16.2 10.8 16.2 10.8 16.2 6 (16,2) 0.934
15B/C 35 (3.7) 2.9 8.6 0.0 22.9 11.4 31.4 3 (8,6) 0.255
35B 34 (3.6) 38.2 8.8 5.9 38.2 2.9 5.9 3 (8,8) 0.283
35F 33 (3.5) 6.1 3.0 3.0 0.0 0.0 0.0 1 (3,0) 0.050
22F 32 (3.4) 0.0 0.0 0.0 0.0 0.0 0.0 0 (0,0) 0.017*
6A 28 (3.0) 39.3 39.3 10.7 39.3 10.7 25.0 10 (35,7) 0.015*
10A 28 (3.0) 7.1 10.7 7.1 7.1 10.7 10.7 2 (7,1) 0.243
6B 25 (2.7) 24.0 32.0 28.0 20.0 28.0 24.0 8 (32,0) 0.081
15A 24 (2.6) 58.3 62.5 62.5 62.5 50 8.3 15 (62,5) < 0.001*
17F 23 (2.5) 8.7 4.3 4.3 8.7 4.3 0.0 1 (4,3) 0.172
24F 21 (2.2) 28.6 28.6 28.6 28.6 28.6 19.0 6 (28,6) 0.260
18C 20 (2.1) 0.0 0.0 0.0 0.0 0.0 10.0 0 (0,0) 0.079
16F 19 (2.0) 0.0 15.8 15.8 0.0 15.8 42.1 1 (5,3) 0.282
37 17 (1.8) 0.0 0.0 0.0 0.0 0.0 5.9 0 (0,0) 0.117
7F 17 (1.8) 0.0 0.0 0.0 0.0 0.0 0.0 0 (0,0) 0.117
9 N 17 (1.8) 0.0 0.0 0.0 0.0 0.0 0.0 0 (0,0) 0.117
14 16 (1.7) 81.3 31.3 25.0 81.3 18.8 43.8 8 (50,0) 0.001*
33F 15 (1.6) 0.0 33.3 33.3 0.0 26.7 6.7 1 (6,7) 0.462
21 13 (1.4) 0.0 0.0 0.0 7.7 0.0 0.0 0 (0,0) 0.201
31 13 (1.4) 0.0 0.0 0.0 0.0 0.0 0.0 0 (0,0) 0.201
34 13 (1.4) 61.5 0.0 0.0 30.8 0.0 23.1 0 (0,0) 0.201
*p < 0.05 is significant; MDR =Multidrug resistance; In bold: serotypes presenting the most MDR isolates; underlined: highly resistance
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serotypes were PPV vaccine or non-vaccine types. The
most prevalent PCV7 vaccine type was 19F. These re-
sults might be explained by a replacement in the sero-
types carriage. Our results are in concordance with an
earlier report have reporting the predominance of
non-vaccine serotypes, among which serotype 11A, in
336 paediatric patients in Ireland [15].
In contrast to previous carriage studies [16–18] which
reported a decrease in pneumococcal carriage after vac-
cine implementation, our analyses show a higher risk of
pneumococcal colonization upon vaccination. Most of
the studies dealing with the effect of vaccination on
pneumococcal carriage were conducted in vaccinated
children and within few years after vaccination [19–24] .
This reflects probably the immediate immunity and in-
direct effect of vaccination on the population. Our find-
ings might be explained by the emergence of non-
vaccine serotypes that co-circulated but were suppressed
by vaccine serotypes. Another possible explanation could
be that the protective effect of vaccination against
pneumococcal carriage might decrease over time, allow-
ing a re-emergence of vaccine serotypes in vaccinated
patients. These results are supported by Principi et al.,
[25] who found that pneumococcal prevalence was
higher in vaccinated individuals than in unvaccinated
ones in a study enrolling 2076 children and adolescents
from Italy.
Our results have shown that pneumococcal vaccin-
ation was associated with an increase in the prevalence
of pneumococcal antimicrobial resistance. This may be
explained by the fact that a vaccination might facilitate
the introduction of new pneumococcal serotypes which
are more resistant to antimicrobial agents [26] due to
the replacement of vaccine serotypes [27].
A large variation in serotype distribution as well as in
antimicrobial resistant serotypes was observed in the par-
ticipating countries. In some countries, some serotypes
were associated to resistance (19A and 14 resistance peni-
cillin and ceftazidime). This might be due to differences in
antimicrobial agents use between the participating coun-
tries [28], clonal spread of resistant microorganisms and
antimicrobial cross-resistance between members of anti-
microbial agents classes. This variation might justify the ne-
cessity of implementation of guidelines on antimicrobial
agents use at country level.
Serotype 19A, a PCV-13 vaccine serotype, is the most
frequent causative agent of invasive pneumococcal dis-
eases All participants were provided a written consent
form. For children consent was obtained from one of the
parents or guardians. [29]. In our study, this serotype
was also one of the most frequent carriage isolates
(5.5%, n = 52) and one of the most resistant serotype to
all antimicrobial agents tested. These results are in ac-
cordance with earlier reports [30].
Hackel et al., reported that serotype 15A was highly
resistant to erythromycin and penicillin in clinical strains
worldwide [31]. In our study, 15A representing 2.6% of
all pneumococcal isolates (n = 24), was one of the most
resistant serotypes to penicillin, ceftazidime, clarithro-
mycin, clindamycin and tetracycline. Serotype 35B was,
after 15A, the second most resistant non-vaccine sero-
type to penicillin and ceftazidime (38.2% of serotype 35B
strains were resistant for both antibiotics). In the US,
this serotype is becoming the dominating serotype in
Table 7 Effect of pneumococcal vaccination and vaccination variables (dose, conduction of catch up campaign, year of
implementation, vaccine type and extent of vaccination program), on carriage of antimicrobial resistant pneumococcus (resistant to
at least one antibiotic) in the participating individuals
Models Reference variable Comparative variables OR* p value**
Basic model:
Model 1: vaccination Vaccinated Not vaccinated 0.60 (0.37–0.96) 0.03**
Unknown vaccination
status
0.63 (0.33–1.18) 0.15
Models after addition vaccination program characteristics separately:
Model 2: vaccine dose 2 + 1b 3+1a 0.91 (0.35–2.32) 0.84
Model 3: catch up campaign conduction Catch up campaign conducted c No catch up campaign
conducted d
1.57 (0.65–3.79) 0.32
Model 4: period since vaccine implementation implemented for one year implemented for more
than one year
1.10 (0.90–1.34) 0.34
Model 5: vaccine type PCV 10 PCV 7 1.23 (0.39–3.87) 0.72
PCV 13 0.87 (0.27–2.72) 0.81
Model 6: extent of vaccination program risk based and universal e Universal f 0.69 (0.17–2.81) 0.61
Risk based g 1.07 (0.24–4.69) 0.92
*p < 0.05 is significant
a) Austria, Hungary, Netherlands, Spain, b) Belgium, France, Hungary, Sweden, UK, c) Belgium, FR, Hungary, UK, d) Austria, Hungary, Netherlands, Spain, Sweden, e)
France, f) Austria, Belgium, Hungary, Netherlands, Sweden, UK, g) Hungary, Spain
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carriage and invasive pneumococcal disease, This is due
to a clonal shift after the implementation of PCV7 and a
spread of a β –lactam resistant clonal complex after the
implementation of PCV13 [8, 32].
Conclusions
In conclusion, pneumococcal vaccination is associated
with a higher risk of non PCV10 serotypes colonization
and antimicrobial resistance independently of country
and vaccine used. Serotypes 14 (PCV-7), 15A (non-vac-
cine serotype) and 19A (PCV-13) had the highest pro-
portion of antimicrobial resistance and multidrug
resistance. The emergence of new serotypes and related
prevalence of antimicrobial resistance might justify at
the short-term, a continuous evaluation and adjustment
of available vaccines, in order to include newly emerged
serotypes. At the long-term, the implementation of new
vaccines that could cover all pneumococcal serotypes
such as whole cell vaccines, might be helpful.
Additional file
Additional file 1: Table S1. a: Infants vaccination in National Immunization
Program in the nine participating countries. b: Vaccination in elderly and risk
patients in the nine participating countries. Table S2. Association between age
and vaccination status in (non-) vaccinated participants in participants with
known age range. Table S3. Serotypes distribution by country (%). Serotypes
listed in order from highest to lowest in frequency among all S. pneumoniae
strains cultured in the study as reported in the last column. Table S4. Serotypes
distribution by age category (%). Serotypes listed in order from highest to lowest
in frequency. Only serotypes represented by more than 10 strains among all S.
pneumoniae strains cultured in the study are reported. Correlation between
serotypes frequency in different age groups is shown in the last column.
Table S5. Primers used in this study. (DOCX 67 kb)
Abbreviations
APRES: “The Appropriateness of prescribing antimicrobial agents in primary
health care in Europe with respect to antimicrobial resistance” study;
CDC: Centers for Disease Control and Prevention; CST: Capsular Sequence
Typing; CT: capsular sequence type; EUCAST: European Committee on
Antimicrobial Susceptibility Testing; GP: general practitioners; NIP: National
Immunization Programs; NVT: strains non-vaccine type; PCR: Polymerase
Chain Reaction; PCV: pneumococcal conjugate vaccine; PPV: pneumococcal
polysaccharide vaccine; RIVM: The National Institute for Public Health and the
Environment; VT: vaccine serotype
Acknowledgements
We thank all members of medical microbiology laboratory at Maastricht
University Medical Centre (MUMC) and the National Institute for Public
Health and the Environment (RIVM) for their support.
Funding
This study has been funded by the European Commission - DG Research
within its 7th Framework Program (Grant Agreement 223083).
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
CDJH, WJP and EES coordinated the strain collection as members of the
APRES study. RYY performed the data analysis, the strains identification and
the antimicrobial susceptibility. HJB and GNP performed the Capsular
Sequence Typing (CST). WJP and PS performed the multilevel logistic
regression. RYY, HJB, KT and EES interpreted the results. RYY, HJB K.T and EES
drafted the manuscript. All authors have read and approved the final
manuscript.
Ethics approval and consent to participate
Ethical approval for this study has been obtained in all of the participating
countries, from the following ethics committees:
 Austria: Ethik-Kommission der Medizinischen Universität Wien und des
Allgemeinen Krankenhauses der Stadt Wien Akh (number: 568/2010)
 Belgium: Commissie Medische Ethiek van de Universitaire
Ziekenhuizen K.U.Leuven (number: ML6355)
 Croatia: Sveučilišta u Zagrebu Medicinski Fakultet Ethical Committee
(number: 04–77/2010–246)
 France: Comité de protection des personnes CPP “Ile-de-France III”
(number: 2010-A01004–35 (2853))
 Hungary: Egészségügyi Tudományos Tanács, Tudományos es Kutatásetikai
Bizottság (ETT TUKEB) (number:5635–0/2010-1018EKU (401/PI/010)
 The Netherlands: Medisch Ethische Commissie azM/UM
(number: MEC 10–4-030.4/pl)
 Spain: Clinical Ethics Committee of the IDIAP Jordi Gol and Gurina
(number: P10/55)
 Sweden: Regionala Etikprövningsnämnden i Linköping
(number: 2010–326-31)
All participants provided written informed participatory consent and in the
case of children aged less than 16, their parents or guardians provided
written informed participatory consent on their behalf.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Maastricht University Medical Centre/CAPHRI, Maastricht, The Netherlands.
2Haga hospital, Department medical microbiology, The Hague, The
Netherlands. 3Centre for Infectious Diseases Research Control, National
Institute for Public Health and the Environment, Bilthoven, The Netherlands.
4NIVEL, The Netherlands Institute for Health Services Research, Utrecht, The
Netherlands. 5Department of Primary and Community Care, Radboud
University Nijmegen Medical Centre, Nijmegen, The Netherlands. 6Paediatric
Immunology and Infectious Diseases, Wilhelmina Children’s Hospital,
University Medical Centre Utrecht, Utrecht, The Netherlands.
Received: 18 February 2018 Accepted: 17 August 2018
References
1. Gray BM, Dillon HC Jr. Clinical and epidemiologic studies of pneumococcal
infection in children. Pediatr Infect Dis. 1986;5(2):201–7.
2. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus
pneumoniae virulence factors in host respiratory colonization and disease.
Nat Rev Microbiol. 2008;6(4):288–301.
3. Kay EJ, Yates LE, Terra VS, Cuccui J, Wren BW. Recombinant expression of
Streptococcus pneumoniae capsular polysaccharides in Escherichia coli. Open
Biol. 2016;6(4):150243.
4. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after
pneumococcal vaccination. Lancet. 2011;378(9807):1962–73.
5. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R,
Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al. Decline in invasive
pneumococcal disease after the introduction of protein-polysaccharide
conjugate vaccine. N Engl J Med. 2003;348(18):1737–46.
Yahiaoui et al. BMC Infectious Diseases  (2018) 18:440 Page 9 of 10
6. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR.
Decline in pneumonia admissions after routine childhood immunisation
with pneumococcal conjugate vaccine in the USA: a time-series analysis.
Lancet. 2007;369(9568):1179–86.
7. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas
AR, Harrison LH, Bennett NM, Farley MM, et al. Effect of introduction of the
pneumococcal conjugate vaccine on drug-resistant Streptococcus
pneumoniae. N Engl J Med. 2006;354(14):1455–63.
8. Metcalf BJ, Gertz RE Jr, Gladstone RA, Walker H, Sherwood LK, Jackson D, Li
Z, Law C, Hawkins PA, Chochua S, et al. Strain features and distributions in
pneumococci from children with invasive disease before and after 13-valent
conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2016;
22(1):60. e69–60 e29
9. Centers for Disease C, Prevention. Progress in introduction of
pneumococcal conjugate vaccine - worldwide, 2000-2012. MMWR Morbidity
and mortality weekly report. 2013;62(16):308–11.
10. van Bijnen EM, den Heijer CD, Paget WJ, Stobberingh EE, Verheij RA,
Bruggeman CA, Pringle M, Goossens H, Schellevis FG. The appropriateness
of prescribing antibiotics in the community in Europe: study design. BMC
Infect Dis. 2011;11:293.
11. Elberse KE, van de Pol I, Witteveen S, van der Heide HG, Schot CS, van Dijk A,
van der Ende A, Schouls LM. Population structure of invasive Streptococcus
pneumoniae in the Netherlands in the pre-vaccination era assessed by MLVA
and capsular sequence typing. PLoS One. 2011;6(5):e20390.
12. Mavroidi A, Godoy D, Aanensen DM, Robinson DA, Hollingshead SK, Spratt
BG. Evolutionary genetics of the capsular locus of serogroup 6
pneumococci. J Bacteriol. 2004;186(24):8181–92.
13. EUCAST Definitive Document E.DEF 3.1, June 2000. Determination of
minimum inhibitory concentrations (MICs) of antibacterial agents by agar
dilution. Clin Microbiol Infect 2000. 6(9):509–15.
14. Wyllie AL, Rumke LW, Arp K, Bosch AA, Bruin JP, Rots NY, Wijmenga-
Monsuur AJ, Sanders EA, Trzcinski K. Molecular surveillance on
Streptococcus pneumoniae carriage in non-elderly adults; little evidence for
pneumococcal circulation independent from the reservoir in children. Sci
Rep. 2016;6:34888.
15. McElligott M, Vickers I, Cafferkey M, Cunney R, Humphreys H. Non-invasive
pneumococcal serotypes and antimicrobial susceptibilities in a paediatric
hospital in the era of conjugate vaccines. Vaccine. 2014;32(28):3495–500.
16. Steens A, Caugant DA, Aaberge IS, Vestrheim DF. Decreased carriage and
genetic shifts in the Streptococcus pneumoniae population after changing
the seven-valent to the thirteen-valent pneumococcal vaccine in Norway.
Pediatr Infect Dis J. 2015;34(8):875–83.
17. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A,
Hennessy TW. Indirect effect of conjugate vaccine on adult carriage of
Streptococcus pneumoniae: an explanation of trends in invasive
pneumococcal disease. J Infect Dis. 2006;193(11):1487–94.
18. Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjostrom K,
Morfeldt E, Naucler P, Blennow M, Ortqvist A, et al. Effects of PCV7 and
PCV13 on invasive pneumococcal disease and carriage in Stockholm,
Sweden. Eur Respir J. 2016;47(4):1208–18.
19. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L,
Ensor KM, Hackell J, Siber G, et al. Efficacy, safety and immunogenicity
of heptavalent pneumococcal conjugate vaccine in children. Northern
California Kaiser Permanente vaccine study center group. Pediatr Infect
Dis J. 2000;19(3):187–95.
20. Impact of childhood pneumococcal vaccination programmes and activities
for pneumococcal vaccines in the EU and EEA \EFTA countries. [http://
venice.cineca.org/VENICE_Survey_PNC_1_2012-02-24.pdf]. Accessed 2011.
21. Grall N, Hurmic O, Al Nakib M, Longo M, Poyart C, Ploy MC, Varon E,
Raymond J. Epidemiology of Streptococcus pneumoniae in France before
introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis. 2011;
22. Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S,
Klok R, Papanicolaou S. Cost-effectiveness of 13-valent pneumococcal
conjugate vaccine: Germany, Greece, and the Netherlands. J Inf Secur. 2012;
64(1):54–67.
23. Thoon KC, Chong CY, Tee NW. Early impact of pneumococcal conjugate
vaccine on invasive pneumococcal disease in Singapore children, 2005
through 2010. Int J Infect Dis. 2012;16(3):e209–15.
24. Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L.
Prevention of pneumococcal diseases in the post-seven valent vaccine era:
a European perspective. BMC Infect Dis. 2012;12:207.
25. Principi N, Terranova L, Zampiero A, Montinaro V, Ierardi V, Peves Rios W,
Pelucchi C, Esposito S. Pharyngeal colonization by Streptococcus
pneumoniae in older children and adolescents in a geographical area
characterized by relatively limited pneumococcal vaccination coverage.
Pediatr Infect Dis J. 2015;34(4):426–32.
26. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance
among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric
population after the introduction of 7-valent pneumococcal vaccine in the
United States. Pediatr Infect Dis J. 2007;26(2):123–8.
27. Leibovitz E. The effect of vaccination on Streptococcus pneumoniae
resistance. Curr Infect Dis Rep. 2008;10(3):182–91.
28. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic
use in Europe and association with resistance: a cross-national database
study. Lancet. 2005;365(9459):579–87.
29. Navarro Torne A, Dias JG, Quinten C, Hruba F, Busana MC, Lopalco PL, Gauci
AJ, Pastore-Celentano L, disease Ecefp. European enhanced surveillance of
invasive pneumococcal disease in 2010: data from 26 European countries in
the post-heptavalent conjugate vaccine era. Vaccine. 2014;32(29):3644–50.
30. Song JH, Dagan R, Klugman KP, Fritzell B. The relationship between
pneumococcal serotypes and antibiotic resistance. Vaccine. 2012;30(17):
2728–37.
31. Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, Purdy J.
Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae
clinical isolates among global populations. Vaccine. 2013;31(42):4881–7.
32. Chochua S, Metcalf BJ, Li Z, Walker H, Tran T, McGee L, Beall B. Invasive
serotype 35B pneumococci including an expanding serotype switch
lineage, United States, 2015-2016. Emerg Infect Dis. 2017;23(6):922–30.
Yahiaoui et al. BMC Infectious Diseases  (2018) 18:440 Page 10 of 10
